Novartis' Cosentyx intravenous formulation gains FDA approval, expanding its footprint in the US autoimmune disease market.
First FDA Approval of an Intravenous Formulation and Its Significance
Novartis's flagship interleukin‑17A (IL‑17A) inhibitor, Cosentyx (secukinumab), in an intravenous (IV) formulation has received FDA product approval (BLA 761349) and entered the U.S. market. This approval is highly significant because it offers a new hospital‑administered option that goes beyond the subcutaneous (SC) formulation traditionally used for autoimmune diseases. Patients can now receive IV treatment for active psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non‑radiographic axial spondyloarthritis (nr‑axSpA). Because the infusion takes only 30 minutes once a month, it provides a breakthrough alternative for patients who are uncomfortable with self‑injection or who prefer close clinical monitoring.
Model‑Informed Drug Development (MIDD)–Based Innovative Approval Pathway
The IV formulation was approved without a large, dedicated Phase 3 trial by leveraging a regulatory‑endorsed predictive model under Model‑Informed Drug Development (MIDD). The approach used established safety and efficacy data from the SC formulation to conduct pharmacokinetic (PK) simulations that demonstrated equivalent systemic exposure. The FDA’s acceptance of this simulation‑based pathway sets a precedent for substantially reducing development costs and timelines. As a result, patients can access new therapeutic options more quickly, and Novartis efficiently expands its portfolio.
Differentiated Positioning and Market Landscape Shift
Cosentyx IV is the first and only IL‑17A inhibitor delivered intravenously for these indications, and the only non‑TNF IV therapy in this space. The IV market has been dominated by TNF inhibitors such as Humira (adalimumab) and Remicade (infliximab); this approval gives Novartis a unique foothold. For patients who do not respond to or cannot tolerate TNF blockers, the IV IL‑17A option offers a powerful alternative, likely reshaping the market. Compared with competing SC products such as Eli Lilly’s Taltz (ixekizumab) and UCB’s Bimzelx (bimekizumab), Cosentyx IV provides a clear convenience advantage.
Revenue Growth and Healthcare Cost Efficiency
Cosentyx already generated $6.18 billion in 2023 and $6.668 billion in 2024 in global sales, establishing it as a mega‑blockbuster. The addition of an IV formulation is expected to add momentum to revenue growth. In the U.S., IV drugs fall under Medicare Part B, reducing out‑of‑pocket costs for patients and creating favorable reimbursement for hospitals. Payers may also view the IV option as a way to mitigate non‑adherence risks associated with high‑cost self‑injectables, encouraging favorable formulary placement. Consequently, Novartis is positioned to maximize commercial returns while solidifying its dominance in the autoimmune market.
The FDA approval of Novartis’s Cosentyx IV formulation serves as a short‑term catalyst to drive additional growth for a core asset that already generates roughly $6 billion in annual revenue. Reaching the final “Approved” status without further clinical trials, the product becomes the first IL‑17A mechanism to enter the autoimmune IV market, which has been dominated by TNF inhibitors such as Humira, thereby securing a proprietary niche. From a development perspective, the approval based solely on MIDD simulations and PK matching to existing SC data, without a large Phase 3 trial, establishes a new benchmark for future formulation‑change drug development. In the medium to long term, Medicare Part B coverage in the United States will maximize prescribing convenience, allowing Novartis to outpace competing SC pipelines such as Eli Lilly’s Taltz and further cement its market share.
Source: openFDA (api_fda)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=BLA761349